PXD029793-1

PXD029793 is an original dataset announced via ProteomeXchange.

Title	Serum proteomic profile of asthmatic patients after 6 months of Benralizumab and Mepolizumab treatment
Description	Severe eosinophilic asthma is characterized by chronic airway inflammation, oxidative stress and elevated proinflammatory cytokines, especially IL-5. Mepolizumab and benralizumab are both humanized IgG antibodies directed against IL-5 signaling, directly acting on eosinophils count. Together with the complexity of severe asthma classification and to the patient selection for the targeted treatment, there is also the urgency to clarify the follow-up of therapy to identify biomarkers, in addition to eosinophils, for the optimal duration of treatment, persistence of effectiveness and safety. To this purpose, here we performed a follow-up study by differential proteomic analysis on serum samples after 1 month and 6 months of both therapies and sera from healthy patients. Statistical analysis by PCA and heatmap analyses were performed, and identified proteins were used for enrichment analysis by MetaCore software. Analysis highlights 82 differences among all considered conditions. In particular, 30 referred to benralizumab time points (T0, T1B, T6B) and 24 to mepolizumab time points (T0, T1M, T6M) analyses. t-SNE and heatmap analyses evidences as the differential serum protein profile at 6 months of both treatments is more similar to that of the healthy subjects. Among the identified proteins, APOAI, APOC-II and APOC-III are up-regulated principally after six months of benralizumab treatment, plasminogen is up-regulated after six months of both treatments and ceruloplasmin, up-regulated already after 1 month of benralizumab, become higher after 6 months of mepolizumab. By enrichment analysis, identified proteins were related to lipid metabolism and transport, blood coagulation and ECM remodelling.
HostingRepository	PRIDE
AnnounceDate	2022-04-01
AnnouncementXML	Submission_2022-04-01_04:13:39.272.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Lorenza Vantaggiato
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	No PTMs are included in the dataset
Instrument	ultraflex

Revision	Datetime	Status	ChangeLog Entry
0	2021-11-17 23:56:37	ID requested
⏵ 1	2022-04-01 04:13:39	announced

Dataset with its publication pending

submitter keyword: Mepolizumab

Benralizumab

ceruloplasmin

plasminogen

ApoA1, ApoC, severe eosinophilic asthma.

Professor Luca Bini
contact affiliation	Functional proteomis lab, Life Sciences Dept., University of Siena
contact email	luca.bini@unisi.it
lab head
Lorenza Vantaggiato
contact affiliation	university of siena
contact email	lorenz.vantaggiato@student.unisi.it
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/04/PXD029793

PRIDE project URI

• PRIDE
  1. PXD029793
     1. Label: PRIDE project
     2. Name: Serum proteomic profile of asthmatic patients after 6 months of Benralizumab and Mepolizumab treatment